Cadrenal Therapeutics (CVKD)

• Market cap: $25.9M
• 1 day: -5.32%
• 5 days: -6.37%
• 1 month: -3.14%
• 3 months: -3.73%
• 6 months: -36.39%
• Year to date: -18.45%
• 1 year: 6.94%
• 5 years: -79.55%
• 10 years: -79.55%
• Sector: Healthcare
• Industry: Biotechnology

About: Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Employees: 4

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6% more funds holding

Funds holding: 16 [Q1] → 17 (+1) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.21% less ownership

Funds ownership: 3.69% [Q1] → 3.48% (-0.21%) [Q2]

33% less capital invested

Capital invested by funds: $1.22M [Q1] → $825K (-$398K) [Q2]